📊 ELDN Key Takeaways
Is Eledon Pharmaceuticals, Inc. (ELDN) a Good Investment?
Eledon Pharmaceuticals is a pre-revenue clinical-stage pharmaceutical company with severe cash burn and unsustainable operating losses. The company is burning through cash at an annual rate of $62.3M while generating zero revenue, with current cash reserves of only $22.8M providing minimal runway. The negative profitability metrics and substantial accumulated losses indicate the company is not yet at commercial viability and faces significant execution risk.
Eledon Pharmaceuticals remains a pre-revenue development-stage biotech with no operating income and substantial recurring losses, so current fundamentals do not yet support a strong positive view. The balance sheet is a relative strength because liquidity is high and leverage is minimal, but negative operating cash flow and free cash flow indicate ongoing dependence on cash reserves or future capital raises. Until the company shows meaningful clinical and commercial progress translating into revenue, fundamentals remain weak.
Why Buy Eledon Pharmaceuticals, Inc. Stock? ELDN Key Strengths
- Strong liquidity position with 7.40x current ratio providing short-term solvency buffer
- Minimal leverage with 0.00x debt-to-equity ratio reducing financial stress from debt obligations
- Reasonable balance sheet with $169.0M in total assets and positive stockholders equity of $81.1M
- Strong liquidity profile with 7.40x current and quick ratios
- Debt-free balance sheet reduces financial risk
- Net loss per share improved year over year, indicating some dilution or cost-control benefit
ELDN Stock Risks: Eledon Pharmaceuticals, Inc. Investment Risks
- Zero revenue generation indicates no approved commercial products or sales traction
- Severe negative operating cash flow of -$62.3M annually with only $22.8M cash reserves suggests <5 months of runway without additional funding
- Consistent operating losses of -$45.6M and negative ROE of -56.3% demonstrate the company is value-destructive and far from profitability
- Pre-revenue stage implies all value depends on successful drug development and FDA approval with inherent binary outcome risk
- Significant ongoing cash burn rate unsustainable without successful capital raises or major clinical trial success
- No revenue base, making profitability and margin analysis impossible
- Heavy cash burn with operating cash flow of -$62.34M and free cash flow of -$62.36M
- Negative returns on equity and assets show inefficient capital use and continued operating weakness
Key Metrics to Watch
- Cash burn rate and months of runway remaining
- Clinical trial progress and regulatory milestones for pipeline products
- Capital raise activity and equity dilution from future financing rounds
- Quarterly operating cash burn relative to cash and equivalents
- Any emergence of collaboration revenue, milestone payments, or commercialization progress
Eledon Pharmaceuticals, Inc. (ELDN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.40x current ratio provides a solid financial cushion.
ELDN Profit Margin, ROE & Profitability Analysis
ELDN vs Healthcare Sector: How Eledon Pharmaceuticals, Inc. Compares
How Eledon Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Eledon Pharmaceuticals, Inc. Stock Overvalued? ELDN Valuation Analysis 2026
Based on fundamental analysis, Eledon Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Eledon Pharmaceuticals, Inc. Balance Sheet: ELDN Debt, Cash & Liquidity
ELDN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Eledon Pharmaceuticals, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.66 indicates the company is currently unprofitable.
ELDN Revenue Growth, EPS Growth & YoY Performance
ELDN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2017 | N/A | -$3.9M | N/A |
| Q3 2016 | N/A | -$9.3M | N/A |
| Q2 2016 | N/A | -$9.0M | N/A |
| Q1 2016 | N/A | -$11.4M | N/A |
| Q3 2015 | N/A | -$6.4M | N/A |
| Q2 2015 | N/A | -$5.9M | N/A |
| Q1 2015 | N/A | -$4.8M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Eledon Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
ELDN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Eledon Pharmaceuticals, Inc. (CIK: 0001404281)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ELDN
What is the AI rating for ELDN?
Eledon Pharmaceuticals, Inc. (ELDN) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ELDN's key strengths?
Claude: Strong liquidity position with 7.40x current ratio providing short-term solvency buffer. Minimal leverage with 0.00x debt-to-equity ratio reducing financial stress from debt obligations. ChatGPT: Strong liquidity profile with 7.40x current and quick ratios. Debt-free balance sheet reduces financial risk.
What are the risks of investing in ELDN?
Claude: Zero revenue generation indicates no approved commercial products or sales traction. Severe negative operating cash flow of -$62.3M annually with only $22.8M cash reserves suggests <5 months of runway without additional funding. ChatGPT: No revenue base, making profitability and margin analysis impossible. Heavy cash burn with operating cash flow of -$62.34M and free cash flow of -$62.36M.
What is ELDN's revenue and growth?
Eledon Pharmaceuticals, Inc. reported revenue of $0.0.
Does ELDN pay dividends?
Eledon Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find ELDN SEC filings?
Official SEC filings for Eledon Pharmaceuticals, Inc. (CIK: 0001404281) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ELDN's EPS?
Eledon Pharmaceuticals, Inc. has a diluted EPS of $-0.52.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ELDN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Eledon Pharmaceuticals, Inc. has a SELL rating with 86% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ELDN stock overvalued or undervalued?
Valuation metrics for ELDN: ROE of -56.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ELDN stock in 2026?
Our dual AI analysis gives Eledon Pharmaceuticals, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ELDN's free cash flow?
Eledon Pharmaceuticals, Inc.'s operating cash flow is $-62.3M, with capital expenditures of $17.0K.
How does ELDN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -56.3% (avg: 15%), current ratio 7.40 (avg: 2).